One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients
Authors
Keywords
-
Journal
ACTA PSYCHIATRICA SCANDINAVICA
Volume 139, Issue 1, Pages 26-36
Publisher
Wiley
Online
2018-10-30
DOI
10.1111/acps.12982
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Erratum: Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: A randomized, placebo-controlled trial
- (2018) Bjørn H. Ebdrup et al. DIABETES OBESITY & METABOLISM
- Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis
- (2018) Anthony H. Barnett et al. DIABETES OBESITY & METABOLISM
- Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes
- (2018) Åsa Ericsson et al. PLoS One
- Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1–12.5 Years
- (2018) Jentien M Vermeulen et al. SCHIZOPHRENIA BULLETIN
- Glucagon-like peptide-1 receptor-agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis
- (2018) Dan Siskind et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
- (2018) Patrick M O'Neil et al. LANCET
- Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls
- (2017) Christoph U. Correll et al. World Psychiatry
- Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain—Reply
- (2017) Anders Fink-Jensen et al. JAMA Psychiatry
- Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder
- (2017) Julie R. Larsen et al. JAMA Psychiatry
- Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States
- (2017) B. Hunt et al. JOURNAL OF MEDICAL ECONOMICS
- Physical multimorbidity and psychosis: comprehensive cross sectional analysis including 242,952 people across 48 low- and middle-income countries
- (2016) Brendon Stubbs et al. BMC Medicine
- Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis
- (2016) Dan Siskind et al. BRITISH JOURNAL OF PSYCHIATRY
- Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial
- (2016) Pelle L. Ishøy et al. DIABETES OBESITY & METABOLISM
- Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes
- (2016) Karla Mayfield et al. JOURNAL OF PSYCHOPHARMACOLOGY
- BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment
- (2016) Stephen J Cooper et al. JOURNAL OF PSYCHOPHARMACOLOGY
- The CHANGE trial: no superiority of lifestyle coaching plus care coordination plus treatment as usual compared to treatment as usual alone in reducing risk of cardiovascular disease in adults with schizophrenia spectrum disorders and abdominal obesity
- (2016) Helene Speyer et al. World Psychiatry
- Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis
- (2016) Davy Vancampfort et al. World Psychiatry
- Cardiometabolic Risk Factor Changes Observed in Diabetes Prevention Programs in US Settings: A Systematic Review and Meta-analysis
- (2016) Uma Mudaliar et al. PLOS MEDICINE
- Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis
- (2016) Dan J. Siskind et al. PLoS One
- Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among Persons at Increased Risk: A Systematic Review for the Community Preventive Services Task Force
- (2015) Ethan M. Balk et al. ANNALS OF INTERNAL MEDICINE
- Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention
- (2015) Ulrike Hostalek et al. DRUGS
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder
- (2015) Christoph U. Correll et al. World Psychiatry
- Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis
- (2015) Davy Vancampfort et al. World Psychiatry
- Effect of liraglutide administration and a calorie-restricted diet on lipoprotein profile in overweight/obese persons with prediabetes
- (2014) D. Ariel et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial
- (2014) Julie Rask Larsen et al. BMJ Open
- Metformin for Weight Loss and Metabolic Control in Overweight Outpatients With Schizophrenia and Schizoaffective Disorder
- (2013) L. Fredrik Jarskog et al. AMERICAN JOURNAL OF PSYCHIATRY
- Excess Early Mortality in Schizophrenia
- (2013) Thomas Munk Laursen et al. Annual Review of Clinical Psychology
- Benefits of Liraglutide Treatment in Overweight and Obese Older Individuals With Prediabetes
- (2013) S. H. Kim et al. DIABETES CARE
- Incretin hormones and the satiation signal
- (2013) J J Holst INTERNATIONAL JOURNAL OF OBESITY
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
- (2013) T A Wadden et al. INTERNATIONAL JOURNAL OF OBESITY
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
- (2013) Stefan Leucht et al. LANCET
- A Behavioral Weight-Loss Intervention in Persons with Serious Mental Illness
- (2013) Gail L. Daumit et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits
- (2012) Bjørn H Ebdrup et al. BMC Medicine
- Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: A meta-analytic comparison of randomized controlled trials
- (2012) Jacqueline Caemmerer et al. SCHIZOPHRENIA RESEARCH
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
- (2011) A Astrup et al. INTERNATIONAL JOURNAL OF OBESITY
- Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
- (2011) Marc De Hert et al. Nature Reviews Endocrinology
- Effectiveness of Medications Used to Attenuate Antipsychotic-Related Weight Gain and Metabolic Abnormalities: A Systematic Review and Meta-Analysis
- (2010) Lawrence Maayan et al. NEUROPSYCHOPHARMACOLOGY
- Antipsychotic drugs and obesity
- (2010) Christoph U. Correll et al. TRENDS IN MOLECULAR MEDICINE
- Global Assessment of Functioning (GAF): properties and frontier of current knowledge
- (2010) I. H. Monrad Aas Annals of General Psychiatry
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
- (2009) Arne Astrup et al. LANCET
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started